ReviewJournal of clinical immunology2014
Clinical trials of intravenous immunoglobulin for Alzheimer's disease.
Review in Journal of clinical immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 67 citations in OpenAlex.
- Genetic evidence suggests a protective role of immunoglobulin M in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Immune cells in Alzheimer's disease: insights into pathogenesis and potential therapeutic targets.Medical review (2021) · 2025Review
- Serum immunoglobulins and biomarkers of dementia: a population-based study.Alzheimer's research & therapy · 2023Article
- Recent Trends in Active and Passive Immunotherapies of Alzheimer's Disease.Antibodies (Basel, Switzerland) · 2023Review
- Intruders or protectors - the multifaceted role of B cells in CNS disorders.Frontiers in cellular neuroscience · 2023Review
- The Immune System as a Therapeutic Target for Alzheimer's Disease.Life (Basel, Switzerland) · 2022Review
- The Role of Systemic Filtrating Organs in Aging and Their Potential in Rejuvenation Strategies.International journal of molecular sciences · 2022Review
- Immune Response at the Crossroads of Atherosclerosis and Alzheimer's Disease.Frontiers in cardiovascular medicine · 2022Review
- Linalool Alleviates AOxidative medicine and cellular longevity · 2021Article
- The Impact of Ageing on the CNS Immune Response in Alzheimer's Disease.Frontiers in immunology · 2021Review
- B cells in autoimmune and neurodegenerative central nervous system diseases.Nature reviews. Neuroscience · 2019Review
- Plasma-Based Strategies for Therapeutic Modulation of Brain Aging.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2019Review
- IVIG Delays Onset in a Mouse Model of Gerstmann-Sträussler-Scheinker Disease.Molecular neurobiology · 2019Article
- Tau-Reactive Endogenous Antibodies: Origin, Functionality, and Implications for the Pathophysiology of Alzheimer's Disease.Journal of immunology research · 2019Review
- Decreased immunoglobulin G in brain regions of elder female APOE4-TR mice accompany with Aβ accumulation.Immunity & ageing : I & A · 2019Article
- Peripheral immune system in aging and Alzheimer's disease.Molecular neurodegeneration · 2018Review
- The effects of human leukocyte antigen DRB1*13 and apolipoprotein E on age-related variability of synchronous neural interactions in healthy women.EBioMedicine · 2018Article
- Intense Focus Yet Many Setbacks for Alzheimer's Disease Drug Development.P & T : a peer-reviewed journal for formulary management · 2018Article
- A vaccine with Aβ oligomer-specific mimotope attenuates cognitive deficits and brain pathologies in transgenic mice with Alzheimer's disease.Alzheimer's research & therapy · 2017Article
- Potential importance of B cells in aging and aging-associated neurodegenerative diseases.Seminars in immunopathology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human polyclonal IgG antibody preparation known as Intravenous Immunoglobulin (IVIG) has been under study as a potential treatment for Alzheimer's disease (AD) since 2002. Preclinical and clinical studies have shown that IVIG has anti-amyloid and immune modulatory properties relevant to treating neurodegenerative disorders. In early stage AD clinical trials, IVIG was found to reduce cognitive decline and increase brain glucose metabolism. Unfortunately, IVIG failed to meet primary outcome objectives in the North American Phase 3 clinical trial in mild to moderate AD. However, positive cognitive signals were observed in pre-planned subgroup analyses among APOE-ε4 carriers and moderately impaired AD patients. Biomarker studies revealed dose dependent increases in plasma and CSF immunoglobulins and decreases in beta amyloid-42 levels. In addition, IVIG treatment was generally safe and well-tolerated. These findings suggest that naturally occurring human anti-amyloid antibodies may play a physiologic role in the clearance of aggregated amyloid proteins. While the results of clinical trials to date do not provide support for the use of IVIG to treat AD at the doses tested, additional studies of IVIG's mechanisms are warranted and may guide the development of more effective therapies for AD in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.